Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Pyrazolo[3,4-d]pyrimidines are privileged scaffolds in medicinal chemistry.
• They act as ATP-isosteres, enabling kinase active site inhibition.
• Their structure allows for targeted modifications to achieve selectivity against oncogenic targets.

Purpose of the Study:

• To review pyrazolo[3,4-d]pyrimidines in clinical trials for oncology.
• To examine recent literature (last 5 years) on these compounds for anticancer indications.

Main Methods:

• Literature search of scientific databases.
• Analysis of compounds in clinical trials.
• Review of published research on pyrazolo[3,4-d]pyrimidines for anticancer use.

Main Results:

• Several pyrazolo[3,4-d]pyrimidines have reached clinical trials.
• Ibrutinib, a BTK inhibitor, is an approved pyrazolo[3,4-d]pyrimidine for B-cell cancers.
• Ongoing research explores diverse anticancer applications.

Conclusions:

• Pyrazolo[3,4-d]pyrimidines represent a promising class of anticancer agents.
• Chemical modifications enable targeting multiple oncogenic kinases.
• Continued investigation is crucial for advancing cancer therapies.